CoChat
Sign Up
Cited by 93

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Cholesterol and statins in Alzheimer’s disease: current controversies.

Fonseca, Ana Catarina R.G., Resende, Rosa, Oliveira, Catarina R., Pereira, Cláudia M.F.·2010·Experimental Neurology
DOI 10.1016/j.expneurol.2009.09.013
Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD) is the principal cause of dementia in older people, and accumulation of amyloid-beta (Abeta) peptide is a crucial event in AD pathogenesis. Despite opposite results found in literature, increased evidence posits that high cholesterol levels enhance the risk to develop AD. In fact, cholesterol metabolism and catabolism are affected in this neurodegenerative disorder. Since amyloid precursor protein (APP) processing and subsequent Abeta production are dependent on membrane cholesterol content and on levels of isoprenoid intermediates in the cholesterol biosynthesis pathway, changes in cholesterol might have different consequences on Abeta formation. These pieces of evidence support that inhibitors of cholesterol synthesis, like statins, could have a therapeutic role in AD. Many studies about the effect of statins use in AD show conflicting results; however, some authors explain it by the differences in administrated doses. Recent studies demonstrate that statins can efficiently decrease Abeta formation from APP and be neuroprotective against the peptide toxicity. Because of the high number of pleiotropic effects of statins, novel molecular mechanisms that account for the beneficial effect of these drugs on AD might be discovered in a near future.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2009.09.013

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 208

  1. Abad-Rodriguez, 2004, Neuronal membrane cholesterol loss enhances amyloid peptide generation, J. Cell Biol., 167, 953, 10.1083/jcb.200404149 · DOI
  2. Akasofu, 2008, Study of neuroprotection of donepezil, a therapy for Alzheimer's disease, Chem.-Biol. Interact., 175, 222, 10.1016/j.cbi.2008.04.045 · DOI
  3. Arispe, 2002, Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AβP (1–40) and (1–42) peptides, FASEB J., 16, 1526, 10.1096/fj.02-0829com · DOI
  4. Bate, 2007, Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Aβ1-42, Neuropharmacology, 53, 222, 10.1016/j.neuropharm.2007.05.003 · DOI
  5. Beeri, 2006, Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers, Neurology, 66, 1399, 10.1212/01.wnl.0000210447.19748.0b · DOI
  6. Bi, 2004, Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia, J. Biol. Chem., 279, 48238, 10.1074/jbc.M405442200 · DOI
  7. Bieschke, 2005, Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation, Biochemistry, 44, 4977, 10.1021/bi0501030 · DOI
  8. Blanco-Colio, 2002, 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation, Atherosclerosis, 161, 17, 10.1016/S0021-9150(01)00613-X · DOI
  9. Bodovitz, 1996, Cholesterol modulates α-secretase cleavage of amyloid precursor protein, J. Biol. Chem., 271, 4436, 10.1074/jbc.271.8.4436 · DOI · Paper page
  10. Borronia, 2004, Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer disease: from risk factors to disease modulators, Neurobiol. Aging, 25, 747, 10.1016/j.neurobiolaging.2003.08.004 · DOI
  11. Bösel, 2005, Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones, J. Neurochem., 92, 1386, 10.1111/j.1471-4159.2004.02980.x · DOI
  12. Burns, 2003, Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease, Neurochem. Res., 21, 979, 10.1023/A:1023294820218 · DOI
  13. Burns, 2003, Presenilin redistribution associated with aberrant cholesterol transport enhances β-amyloid production in vivo, J. Neurosci., 23, 5645, 10.1523/JNEUROSCI.23-13-05645.2003 · DOI
  14. Burns, 2006, Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice, Neuromol. Med., 8, 319, 10.1385/NMM:8:3:319 · DOI
  15. Busciglio, 1993, Generation of, β-amyloid in the secretory pathway in neuronal and nonneuronal cells, Proc. Natl. Acad. Sci. U. S. A., 90, 2092, 10.1073/pnas.90.5.2092 · DOI · Paper page
  16. Buxbaum, 1998, Evidence that tumor necrosis factor a converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor, J. Biol. Chem., 273, 27765, 10.1074/jbc.273.43.27765 · DOI
  17. Buxbaum, 2001, Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide, J. Alzheimer's Dis., 3, 221, 10.3233/JAD-2001-3207 · DOI
  18. Buxbaum, 2002, Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer β-amyloid peptide in vitro and in patients, Front. Biosci., 7, a50
  19. Calleros, 2006, RhoA and p38 MAPK mediate apoptosis induced by cellular cholesterol depletion, Apoptosis, 11, 1161, 10.1007/s10495-006-6980-3 · DOI
  20. Casserly, 2004, Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins, Lancet, 363, 1139, 10.1016/S0140-6736(04)15900-X · DOI · Paper page
  21. Cerezo-Guisado, 2005, Lovastatin inhibits the growth and survival pathway of phosphoinositide 3-kinase/protein kinase B in immortalized rat brain neuroblasts, J. Neurochem., 94, 1277, 10.1111/j.1471-4159.2005.03345.x · DOI
  22. Chong, 2001, Clinically relevant differences between the statins: implications for therapeutic selection, Am. J. Med., 111, 390, 10.1016/S0002-9343(01)00870-1 · DOI
  23. Cibičková, 2007, Differential effects of statins and alendronate on cholinesterases in serum and brain of rats, Physiol. Res., 56, 765, 10.33549/physiolres.931121 · DOI
  24. Clarke, 2007, The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-β1-42 in the rat hippocampus in vivo, Neuropharmacology, 52, 136, 10.1016/j.neuropharm.2006.07.031 · DOI
  25. Clarke, 2008, A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain, J. Biol. Chem., 283, 1808, 10.1074/jbc.M707442200 · DOI
  26. Cole, 2005, Statins cause intracellular accumulation of amyloid precursor protein, β-secretase-cleaved fragments, and amyloid β-peptide via an isoprenoid-dependent mechanism, J. Biol. Chem., 280, 18755, 10.1074/jbc.M413895200 · DOI
  27. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
  28. Cordle, 2005, 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses, J. Neurosci., 25, 299, 10.1523/JNEUROSCI.2544-04.2005 · DOI
  29. Crestini, 2006, Changes in cholesterol metabolism are associated with PS1 and PS2 gene regulation in SK-N-BE, J. Mol. Neurosci., 30, 311, 10.1385/JMN:30:3:311 · DOI
  30. Crisby, 2002, Statins in the prevention and treatment of Alzheimer disease, Alzheimer Dis. Assoc. Disord., 16, 131, 10.1097/00002093-200207000-00001 · DOI
  31. Cutler, 2004, Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease, Proc. Natl. Acad. Sci., 101, 2070, 10.1073/pnas.0305799101 · DOI · Paper page
  32. De Strooper, 2003, Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex, Neuron, 38, 9, 10.1016/S0896-6273(03)00205-8 · DOI · Paper page
  33. Désiré, 2005, RAC1 inhibition targets amyloid precursor protein processing by γ-secretase and decreases Aβ production in vitro and in vivo, J. Biol. Chem., 280, 37516, 10.1074/jbc.M507913200 · DOI
  34. Distl, 2001, Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons, Acta Neuropathol., 101, 547, 10.1007/s004010000314 · DOI
  35. Dominguez, 2004, Nitric oxide mediates glutamate-evoked dopamine release in the medial preoptic area, Neuroscience, 125, 203, 10.1016/j.neuroscience.2004.01.022 · DOI
  36. Dugan, 1995, The Ras-related GTP-binding, Rab1B, regulates early steps in esocytic transport and processing of β-amyloid precursor protein, J. Biol. Chem., 270, 10982, 10.1074/jbc.270.18.10982 · DOI
  37. Ehehalt, 2003, Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts, J. Cell Biol., 160, 113, 10.1083/jcb.200207113 · DOI · Paper page
  38. Ehrenstein, 2005, Statins for atherosclerosis—as good as it gets?, N. Engl. J. Med., 252, 73, 10.1056/NEJMe048326 · DOI
  39. Endo, 1976, Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity, FEBS Lett., 72, 323, 10.1016/0014-5793(76)80996-9 · DOI
  40. Endres, 2005, Statins and stroke, J. Cereb. Blood Flow Metab., 25, 1093, 10.1038/sj.jcbfm.9600116 · DOI
  41. Famer, 2004, Rosuvastatin reduces caspase-3 activity and up-regulates α-secretase in human neuroblastoma SH-SY5Y cells exposed to Aβ, Neurosci. Lett., 271, 209, 10.1016/j.neulet.2004.08.069 · DOI
  42. Fan, 2001, Cholesterol-dependent modulation of tau phosphorylation in cultured neurons, J. Neurochem., 76, 391, 10.1046/j.1471-4159.2001.00063.x · DOI
  43. Fan, 2002, Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons, J. Neurochem., 80, 178, 10.1046/j.0022-3042.2001.00686.x · DOI
  44. Farhangrazi, 1997, High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture, NeuroReport, 8, 1127, 10.1097/00001756-199703240-00013 · DOI
  45. Farzan, 2000, BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein, Proc. Natl. Acad. Sci., 97, 9712, 10.1073/pnas.160115697 · DOI · Paper page
  46. Fassbender, 2001, Simvastatin strongly reduces levels of Alzheimer's disease b-amyloid peptides Ab42 and Ab40 in vitro and in vivo, Proc. Natl. Acad. Sci., 98, 5856, 10.1073/pnas.081620098 · DOI · Paper page
  47. Ferreiro, 2008, The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway, Neurobiol. Dis., 30, 331, 10.1016/j.nbd.2008.02.003 · DOI
  48. Fischer, 2001, Brain dendritic cells and macrophages/microglia in central nervous system inflammation, J. Immunol., 166, 2717, 10.4049/jimmunol.166.4.2717 · DOI
  49. Fonseca, A.C., Proena, T., Resende, R., Oliveira, C.R., Pereira, C.M.F., 2009. Neuroprotective effects of statins in an in vitro model of Alzheimer's disease. J. Alzheimer's Dis. 17, 503–517. · DOI
  50. Franke, 2007, Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment, Neurobiol. Dis., 25, 438, 10.1016/j.nbd.2006.10.004 · DOI
  51. Frears, 1999, The role of cholesterol in the biosynthesis of β-amyloid, NeuroReport, 10, 1699, 10.1097/00001756-199906030-00014 · DOI
  52. García-Román, 2001, Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition, Mol. Cell. Neurosci., 17, 329, 10.1006/mcne.2000.0904 · DOI
  53. Gellermann, 2006, Alzheimer-like plaque formation by human macrophages Is reduced by fibrillation inhibitors and lovastatin, J. Mol. Biol., 360, 251, 10.1016/j.jmb.2006.05.026 · DOI
  54. Gong, 2002, Amyloid β-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade, J. Neurosci. Res., 70, 438, 10.1002/jnr.10347 · DOI
  55. Grace, 2002, Characterization of neuronal dystrophy induced by fibrillar amyloid β: implications for Alzheimer's disease, Neuroscience, 114, 265, 10.1016/S0306-4522(02)00241-5 · DOI
  56. Graves, 1999, Cognitive decline and Japanese culture in a cohort of older Japanese Americans in King County, WA: the Kame Project, J. Gerontol., B Psychol. Sci. Soc. Sci., 54, S154, 10.1093/geronb/54B.3.S154 · DOI
  57. Grimm, 2005, Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin, Nat. Cell Biol., 7, 1118, 10.1038/ncb1313 · DOI
  58. Grimm, 2006, Altered membrane fluidity and lipid raft composition in presenilin-deficient cells, Acta Neurol. Scand. Suppl., 185, 27, 10.1111/j.1600-0404.2006.00682.x · DOI
  59. Gustafson, 2003, An 18-year follow-up of overweight and risk of Alzheimer disease, Arch. Intern. Med., 163, 1524, 10.1001/archinte.163.13.1524 · DOI · Paper page
  60. Hartmann, 1997, Distinct sites of intracellular production for Alzheimer's disease Abeta40/42 amyloid peptides, Nat. Med., 3, 1016, 10.1038/nm0997-1016 · DOI
  61. Hayashi, 2004, A seed for Alzheimer amyloid in the brain, J. Neurosci., 24, 4894, 10.1523/JNEUROSCI.0861-04.2004 · DOI
  62. Helzner, 2009, Contribution of vascular risk factors to the progression in Alzheimer disease, Arch. Neurol., 66, 343, 10.1001/archneur.66.3.343 · DOI
  63. Hendrie, 2001, Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana, JAMA, 285, 739, 10.1001/jama.285.6.739 · DOI
  64. Herz, 2000, Apolipoprotein E receptors: linking brain development and Alzheimer's disease, Nat. Rev., Neurosci., 1, 51, 10.1038/35036221 · DOI
  65. Heverin, 2004, Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease, J. Lipid Res., 45, 186, 10.1194/jlr.M300320-JLR200 · DOI
  66. Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet, 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
  67. Höglund, 2004, Plasma levels of β-amyloid(1-40), β-amyloid(1-42), and total β-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins, Arch. Neurol., 61, 333, 10.1001/archneur.61.3.333 · DOI
  68. Höglund, 2005, Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer's disease, Exp. Brain Res., 164, 205, 10.1007/s00221-005-2243-8 · DOI
  69. Honig, 2003, Stroke and the risk of Alzheimer disease, Arch. Neurol., 60, 1707, 10.1001/archneur.60.12.1707 · DOI
  70. Howland, 1998, Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol, J. Biol. Chem., 273, 16576, 10.1074/jbc.273.26.16576 · DOI
  71. Hutter-Paier, 2004, The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease, Neuron, 44, 227, 10.1016/j.neuron.2004.08.043 · DOI · Paper page
  72. Igbavboa, 1996, Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice, J. Neurochem., 66, 1717, 10.1046/j.1471-4159.1996.66041717.x · DOI
  73. Igbavboa, 2003, Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid β-peptide-(1–42), J. Biol. Chem., 278, 17150, 10.1074/jbc.M301150200 · DOI
  74. Istvan, 2002, Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase, Am. Heart J., 144, S27, 10.1067/mhj.2002.130300 · DOI
  75. Istvan, 2003, Statin inhibition of HMG-CoA reductase: a 3-dimensional view, Atheroscler. Suppl., 4, 3, 10.1016/S1567-5688(03)00003-5 · DOI
  76. Jantzen, 2007, Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells, J. Physiol. Pharmacol., 58, 503
  77. Jiang, 2007, The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells, Biochem. Cell. Biol., 85, 66, 10.1139/o06-146 · DOI
  78. Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X · DOI
  79. Jin, 2004, Intracellular accumulation of amyloidogenic fragments of amyloid-β precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities, Am. J. Pathol., 164, 975, 10.1016/S0002-9440(10)63185-9 · DOI
  80. Johnson-Anuna, 2005, Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex, J. Pharmacol. Exp. Ther., 312, 786, 10.1124/jpet.104.075028 · DOI
  81. Johnson-Anuna, 2007, Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein, J. Neurochem., 101, 77, 10.1111/j.1471-4159.2006.04375.x · DOI
  82. Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR⁎ Trial), Am. J. Cardiol., 92, 152, 10.1016/S0002-9149(03)00530-7 · DOI
  83. Kaether, 2004, A lipid boundary separates APP and secretases and limits amyloid β-peptide generation, J. Cell Biol., 167, 809, 10.1083/jcb.200410090 · DOI
  84. Kakio, 2002, Interactions of amyloid β-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer Amyloid, Biochemistry, 41, 7385, 10.1021/bi0255874 · DOI
  85. Kaneko, 2001, Drastic neuronal loss in vivo by β-amyloid racemized at Ser26 residue: conversion of non-toxic [D-Ser26]β-amyloid 1–14 to toxic and proteinase-resistant fragments, Neuroscience, 104, 1003, 10.1016/S0306-4522(01)00155-5 · DOI
  86. Karten, 2002, Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons, J. Neurochem., 83, 1154, 10.1046/j.1471-4159.2002.01220.x · DOI
  87. Kawas, 2000, Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging, Neurology, 54, 2072, 10.1212/WNL.54.11.2072 · DOI · Paper page
  88. Kiener, 2001, Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors, Int. Immunopharmacol., 1, 105, 10.1016/S0162-3109(00)00272-1 · DOI
  89. Kirsh, 2003, Statins effects on cholesterol micro-domains in plasma membranes, Biochem. Pharmacol., 65, 843, 10.1016/S0006-2952(02)01654-4 · DOI
  90. Kivipelto, 2001, Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study, BMJ, 322, 1447, 10.1136/bmj.322.7300.1447 · DOI · Paper page
  91. Kivipelto, 2002, Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease, Ann. Int. Med., 137, 149, 10.7326/0003-4819-137-3-200208060-00006 · DOI
  92. Koike, 1999, Membrane-anchored metalloprotease MDC9 has an a-secretase activity responsible for processing the amyloid precursor protein, Biochem. J., 343, 371, 10.1042/bj3430371 · DOI
  93. Kojro, 2001, Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10, Proc. Natl. Acad. Sci., 98, 5815, 10.1073/pnas.081612998 · DOI · Paper page
  94. Koldamova, 2003, 22R-Hydroxycholesterol and 9-cis-retinoic acid Induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid β secretion, J. Biol. Chem., 278, 13244, 10.1074/jbc.M300044200 · DOI · Paper page
  95. Koudinov, 2001, Essential role for cholesterol in synaptic plasticity and neuronal degeneration, FASEB J., 15, 1858, 10.1096/fj.00-0815fje · DOI
  96. Kuo, 1998, Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1–42 levels, Biochem. Biophys. Res. Commun., 252, 711, 10.1006/bbrc.1998.9652 · DOI · Paper page
  97. Kureishi, 2000, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat. Med., 6, 1004, 10.1038/79510 · DOI
  98. Lacko, 1983, Lecithin: cholesterol acyltransferase in Down's syndrome, Clin. Chim. Acta, 132, 133, 10.1016/0009-8981(83)90241-3 · DOI
  99. Leissring, 2002, A physiologic signaling role for the γ-secretase-derived intracellular fragment of APP, Proc. Natl. Acad. Sci., 99, 4697, 10.1073/pnas.072033799 · DOI
  100. Li, 2005, Effects of Abeta25-35 on neurogenesis in the adult mouse subventricular zone and dentate gyrus, Neurol. Res., 27, 218, 10.1179/016164105X35585 · DOI
  101. Li, 2002, Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells, J. Biol. Chem., 277, 15309, 10.1074/jbc.M201253200 · DOI
  102. Li, 2004, Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study, Neuron, 63, 1624
  103. Li, 2006, Simvastatin enhances learning and memory independent of amyloid load in mice, Ann. Neurol., 60, 729, 10.1002/ana.21053 · DOI
  104. Liu, 1998, Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis, Proc. Natl. Acad. Sci. U. S. A., 95, 13266, 10.1073/pnas.95.22.13266 · DOI
  105. Liu, 2004, Residues 17–20 and 30–35 of beta-amyloid play critical roles in aggregation, J. Neurosci. Res., 75, 162, 10.1002/jnr.10859 · DOI
  106. Locatelli, 2002, Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain, Arch. Neurol., 59, 213, 10.1001/archneur.59.2.213 · DOI
  107. Lütjohann, 2003, 24S-hydroxycholesterol: a marker of brain cholesterol metabolism, Pharmacopsychiatry, 36, S102, 10.1055/s-2003-43053 · DOI
  108. Lütjohann, 2000, Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients, J. Lipid Res., 41, 195, 10.1016/S0022-2275(20)32052-6 · DOI
  109. Mackay, 1998, Rho GTPases, J. Biol. Chem., 273, 20685, 10.1074/jbc.273.33.20685 · DOI
  110. Malaplate-Armand, 2006, Soluble oligomers of amyloid-B peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway, Neurobiol. Dis., 23, 178, 10.1016/j.nbd.2006.02.010 · DOI
  111. Marx, 2001, Alzheimer's disease. Bad for the heart, bad for the mind?, Science, 294, 508, 10.1126/science.294.5542.508 · DOI
  112. Mauch, 2001, CNS synaptogenesis promoted by glia-derived cholesterol, Science, 294, 1354, 10.1126/science.294.5545.1354 · DOI · Paper page
  113. McConlogue, 1996, Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein, J. Biol. Chem., 271, 1343, 10.1074/jbc.271.3.1343 · DOI
  114. Merla, 2007, The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation, Am. J. Physiol., Heart Circ. Physiol., 293, H1918, 10.1152/ajpheart.00416.2007 · DOI
  115. Meske, 2003, Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranyl pyrophosphate formation: implications for Alzheimer's disease, Eur. J. Neurosci., 17, 93, 10.1046/j.1460-9568.2003.02433.x · DOI
  116. Michikawa, 2001, A novel action of Alzheimer's amyloid β-protein (Aβ): oligomeric Aβ promotes lipid release, J. Neurosci., 21, 7226, 10.1523/JNEUROSCI.21-18-07226.2001 · DOI
  117. Mizuno, 1999, Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture, J. Biol. Chem., 274, 15110, 10.1074/jbc.274.21.15110 · DOI
  118. Montaner, 1998, Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases, J. Biol. Chem., 273, 12779, 10.1074/jbc.273.21.12779 · DOI
  119. Mozayan, 2007, Statins prevent cholinesterase inhibitor blockade of sympathetic α7-nAChR-mediated currents in rat superior cervical ganglion neurons, Am. J. Physiol., Heart Circ. Physiol., 293, H1737, 10.1152/ajpheart.00269.2007 · DOI
  120. Mulhaupt, 2003, Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells, Cardiovasc. Res., 59, 755, 10.1016/S0008-6363(03)00515-7 · DOI
  121. Nagy, 2005, The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease, J. Cell Mol. Med., 9, 531, 10.1111/j.1582-4934.2005.tb00485.x · DOI · Paper page
  122. Nelson, 2005, Oxidation of cholesterol by amyloid precursor protein and β-amyloid peptide, J. Biol. Chem., 280, 7377, 10.1074/jbc.M409071200 · DOI
  123. Nixon, 2004, Niemann-Pick type C disease and Alzheimer's disease: the APP-endosome connection fattens up, Am. J. Pathol., 64, 757, 10.1016/S0002-9440(10)63163-X · DOI
  124. Olesen, 2000, High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils, Biochem. Biophys. Res. Commun., 270, 62, 10.1006/bbrc.2000.2372 · DOI
  125. Ong, 2001, Neurodegeneration in Niemann-Pick type C disease mice, Exp. Brain Res., 141, 218, 10.1007/s002210100870 · DOI
  126. Ostrowski, 2007, Statins reduce amyloid-β production through inhibition of protein isoprenylation, J. Biol. Chem., 282, 26832, 10.1074/jbc.M702640200 · DOI · Paper page
  127. Pahan, 1997, Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages, J. Clin. Invest., 100, 2671, 10.1172/JCI119812 · DOI
  128. Panza, 2006, Lipid metabolism in cognitive decline and dementia, Brain Res. Rev., 51, 275, 10.1016/j.brainresrev.2005.11.007 · DOI
  129. Panza, 2007, Total cholesterol levels and the risk of mild cognitive impairment and Alzheimer'disease, JAGS Lett. Ed., 55, 133, 10.1111/j.1532-5415.2006.01003.x · DOI
  130. Papassotiropoulos, 2002, 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia, J. Psychiatr. Res., 36, 27, 10.1016/S0022-3956(01)00050-4 · DOI
  131. Papassotiropoulos, 2003, Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism, Arch. Neurol., 60, 29, 10.1001/archneur.60.1.29 · DOI
  132. Pappolla, 2003, Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology, Neurology, 61, 199, 10.1212/01.WNL.0000070182.02537.84 · DOI · Paper page
  133. Paris, 2002, Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae, Atherosclerosis, 161, 293, 10.1016/S0021-9150(01)00660-8 · DOI
  134. Park, 2003, Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice, Neurobiol. Aging, 24, 637, 10.1016/S0197-4580(02)00155-0 · DOI
  135. Parsons, 2006, Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms, Biochem. J., 399, 205, 10.1042/BJ20060655 · DOI
  136. Petanceska, 2002, Statin therapy for Alzheimer's disease: will it work?, J. Mol. Neurosci., 19, 155, 10.1007/s12031-002-0026-2 · DOI
  137. Poirier, 2000, Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism, Ann. N.Y. Acad. Sci., 924, 81, 10.1111/j.1749-6632.2000.tb05564.x · DOI
  138. Pooler, 2006, The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons, J. Neurochem., 97, 716, 10.1111/j.1471-4159.2006.03763.x · DOI
  139. Postina, 2004, A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model, J. Clin. Invest., 113, 1456, 10.1172/JCI20864 · DOI · Paper page
  140. Puglielli, 2001, Acyl-coenyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide, Nat. Cell Biol., 3, 905, 10.1038/ncb1001-905 · DOI · Paper page
  141. Puglielli, 2003, Alzheimer's disease: the cholesterol connection, Nat. Neurosci., 6, 345, 10.1038/nn0403-345 · DOI · Paper page
  142. Puglielli, 2004, Role of acyl-coenzyme A cholesterol acyltransferase activity in the processing of the amyloid precursor protein, J. Mol. Neurosci., 24, 93, 10.1385/JMN:24:1:093 · DOI
  143. Qiu, 2003, Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community based, longitudinal study, Stroke, 34, 594, 10.1161/01.STR.0000060127.96986.F4 · DOI
  144. Refolo, 2000, Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model, Neurobiol. Dis., 7, 321, 10.1006/nbdi.2000.0304 · DOI · Paper page
  145. Refolo, 2001, A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease, Neurobiol. Dis., 8, 890, 10.1006/nbdi.2001.0422 · DOI
  146. Repetto, 2004, BACE1 overexpression regulates amyloid precursor protein cleavage and interaction with the ShcA adapter, Ann. N.Y. Acad. Sci., 1030, 330, 10.1196/annals.1329.041 · DOI
  147. Resende, 2007, Susceptibility of hippocampal neurons to Aβ peptide toxicity is associated with perturbation of Ca2+ homeostasis, Brain Res., 1143, 11, 10.1016/j.brainres.2007.01.071 · DOI
  148. Romas, 1999, APOE genotype, plasma lipids, lipoproteins, and AD in community elderly, Neurology, 53, 517, 10.1212/WNL.53.3.517 · DOI
  149. Runz, 2002, Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells, J. Neurosci., 22, 1679, 10.1523/JNEUROSCI.22-05-01679.2002 · DOI
  150. Rutishauser, 2006, The role of statins in clinical medicine—LDL-cholesterol lowering and beyond, Swiss Med. Wkly., 136, 41, 10.4414/smw.2006.11170 · DOI
  151. Sabbagh, 2004, Is there a characteristic lipid profile in Alzheimer's disease, J. Alzheimer's Dis., 6, 585, 10.3233/JAD-2004-6602 · DOI · Paper page
  152. Sala, 2008, HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol lowering effects, J. Pharmacol. Exp. Ther., 324, 352, 10.1124/jpet.107.128959 · DOI
  153. Salins, 2007, Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling, Neurosci. Lett., 412, 211, 10.1016/j.neulet.2006.07.045 · DOI
  154. Schneider, 2006, Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons, Neurobiol. Dis., 23, 573, 10.1016/j.nbd.2006.04.015 · DOI
  155. Schönknecht, 2002, Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls, Neurosci. Lett., 324, 83, 10.1016/S0304-3940(02)00164-7 · DOI
  156. Schroeder, 2001, Recent advances in membrane microdomains: rafts, caveolae, and intracellular cholesterol trafficking, Exp. Biol. Med., 226, 873, 10.1177/153537020122601002 · DOI
  157. Schulz, 2004, HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis, J. Neurochem., 89, 24, 10.1046/j.1471-4159.2003.02305.x · DOI
  158. Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X · DOI · Paper page
  159. Shie, 2002, Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice, NeuroReport, 13, 455, 10.1097/00001756-200203250-00019 · DOI · Paper page
  160. Shishehbor, 2003, Statins promote potent systemic antioxidant effects through specific inflammatory pathways, Circulation, 108, 426, 10.1161/01.CIR.0000080895.05158.8B · DOI
  161. Si, 2005, Statins prevent beta-amyloid inhibition of sympathetic alpha7-nAChR-mediated nitrergic neurogenic dilation in porcine basilar arteries, J. Cereb. Blood Flow Metab., 25, 1573, 10.1038/sj.jcbfm.9600232 · DOI
  162. Simons, 1998, Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons, Proc. Natl. Acad. Sci. U. S. A., 95, 6460, 10.1073/pnas.95.11.6460 · DOI
  163. Simons, 2001, Cholesterol and Alzheimer's disease: is there a link?, Neurology, 57
  164. Sjögren, 2003, Treatment with simvastatin in patients with Alzheimer's disease lowers both α- and β-cleaved APP, Dement. Geriatr. Cogn. Disord., 16, 25, 10.1159/000069989 · DOI
  165. Skovronsky, 2000, Protein kinase C-dependent α-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the trans-golgi network, J. Biol. Chem., 275, 2568, 10.1074/jbc.275.4.2568 · DOI
  166. Solfrizzi, 2004, Vascular risk factors, incidence of MCI, and rates of progression to dementia, Neurology, 63, 1882, 10.1212/01.WNL.0000144281.38555.E3 · DOI · Paper page
  167. Sparks, 1990, Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease, Neurobiol. Aging, 11, 601, 10.1016/0197-4580(90)90024-T · DOI
  168. Sparks, 2003, Is cholesterol a culprit in Alzheimer's disease?, Int. Psychogeriatr., 15, 153, 10.1017/S1041610203009128 · DOI
  169. Sparks, 2005, Atorvastatin for the treatment of mild to moderate Alzheimer disease, Arch. Neurol., 62, 753, 10.1001/archneur.62.5.753 · DOI · Paper page
  170. Sponne, 2004, Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of amyloid-β peptide, FASEB J., 18, 836, 10.1096/fj.03-0372fje · DOI
  171. Stephens, 1996, Metabolites of the β-amyloid precursor protein generated by β-secretase localise to the trans-Golgi network and late endosome in 293 cells, J. Neurosci. Res., 46, 211, 10.1002/(SICI)1097-4547(19961015)46:2<211::AID-JNR9>3.0.CO;2-K · DOI
  172. Strittmatter, 1993, Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A., 90, 8098, 10.1073/pnas.90.17.8098 · DOI · Paper page
  173. Subasinghe, 2003, Cholesterol is necessary both for the toxic effect of Aβ peptides on vascular smooth muscle cells and for Aβ binding to vascular smooth muscle cell membranes, J. Neurochem., 84, 471, 10.1046/j.1471-4159.2003.01552.x · DOI
  174. Sun, 2003, Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide Aβ1–42 in glioma cell culture in vitro, Pharmacol. Res., 47, 119, 10.1016/S1043-6618(02)00288-8 · DOI
  175. Svennerholm, 1994, Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years, J. Neurochem., 63, 1802, 10.1046/j.1471-4159.1994.63051802.x · DOI
  176. Tadiboyina, 2005, Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease, Lipids Health Dis., 4, 26, 10.1186/1476-511X-4-26 · DOI
  177. Tanaka, 2000, Geranylgeranyl-pirophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition, J. Neurosci., 20, 2852, 10.1523/JNEUROSCI.20-08-02852.2000 · DOI
  178. Tomita, 1997, The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue, Proc. Natl. Acad. Sci. U. S. A., 94, 2025, 10.1073/pnas.94.5.2025 · DOI
  179. Townsend, 2004, Lovastatin modulation of microglial activation via suppression of functional CD40 expression, J. Neurosci. Res., 78, 167, 10.1002/jnr.20234 · DOI
  180. Urano, 2005, Association of active γ-secretase complex with lipid rafts, J. Lipid Res., 46, 904, 10.1194/jlr.M400333-JLR200 · DOI
  181. Urbich, 2002, Double-edged role of statins in angiogenesis signaling, Circ. Res., 90, 737, 10.1161/01.RES.0000014081.30867.F8 · DOI
  182. Veillard, 2002, Statins: the new aspirin?, Cell. Mol. Life Sci., 59, 1771, 10.1007/PL00012505 · DOI
  183. Vetrivel, 2004, Association of γ-secretase with lipid raft in post-Golgi and endossome membrane, J. Biol. Chem., 279, 44945, 10.1074/jbc.M407986200 · DOI · Paper page
  184. Wagner, 2002, 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells, Arterioscler. Thromb. Vasc. Biol., 22, 1784, 10.1161/01.ATV.0000037098.20829.31 · DOI
  185. Wahrle, 2002, Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains, Neurobiol. Dis., 9, 11, 10.1006/nbdi.2001.0470 · DOI · Paper page
  186. Wang, 2005, High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase, Br. J. Pharmacol., 144, 933, 10.1038/sj.bjp.0706106 · DOI
  187. Weis, 2002, Statins have biphasic effects on angiogenesis, Circulation, 105, 739, 10.1161/hc0602.103393 · DOI
  188. Weitz-Schmidt, 2001, Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site, Nat. Med., 7, 687, 10.1038/89058 · DOI
  189. Wilson, 1997, Free fatty acids stimulate the polymerization of tau and amyloid β peptides: in vitro evidence for a common effector of pathogenesis in Alzheimer's disease, Am. J. Pathol., 150, 2181
  190. Wolf, 2004, Serum lipids and hippocampal volume: the link to Alzheimer's disease?, Ann. Neurol., 56, 745, 10.1002/ana.20289 · DOI
  191. Wolozin, 2001, A fluid connection: cholesterol and Aβ, Proc. Natl. Acad. Sci. U. S. A., 98, 5371, 10.1073/pnas.101123198 · DOI
  192. Wolozin, 2002, Cholesterol and Alzheimer's disease, Biochem. Soc. Trans., 30, 525, 10.1042/bst0300525 · DOI · Paper page
  193. Wolozin, 2004, Cholesterol, statins and dementia, Curr. Opin. Lipid., 15, 667, 10.1097/00041433-200412000-00007 · DOI
  194. Wood, 2002, Brain membrane cholesterol domains, aging and amyloid beta-peptides, Neurobiol. Aging, 23, 685, 10.1016/S0197-4580(02)00018-0 · DOI
  195. Wu, 1996, Changes in membrane properties during energy depletion-induced cell injury studied with fluorescence microscopy, Biophys. J., 71, 91, 10.1016/S0006-3495(96)79243-3 · DOI
  196. Xiao, 2002, Huperzine A attenuates amyloid β-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation, J. Neurosci. Res., 67, 30, 10.1002/jnr.10075 · DOI
  197. Xiu, 2005, Lovastatin stimulates up-regulation of α7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the α-form of secreted amyloid precursor protein, J. Neurosci. Res., 82, 531, 10.1002/jnr.20658 · DOI
  198. Yaffe, 2002, Serum lipoprotein levels, statin use, and cognitive function in older women, Arch. Neurol., 59, 378, 10.1001/archneur.59.3.378 · DOI
  199. Yamazaki, 2001, Accumulation and aggregation of amyloid β-protein in late endosomes of Niemann-pick type C cells, J. Biol. Chem., 276, 4454, 10.1074/jbc.M009598200 · DOI
  200. Yao, 2002, 22R-Hydroxycholesterol protects neuronal cells from beta-amyloid-induced cytotoxicity by binding to beta-amyloid peptide, Neurochemistry, 83, 1110, 10.1046/j.1471-4159.2002.01202.x · DOI

200 of 208 shown

Cited by

Sorted by citations

Metadata

Authors
Fonseca, A. C. R. G., Resende, R., Oliveira, C. R., & Pereira, C. M. F.
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
2010-06
Volume
223
Issue
2
Pages
282-293
ISSN
0014-4886
DOI
10.1016/j.expneurol.2009.09.013
Cited by
93
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review